Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated by Analysts at StockNews.com

Posted by on Apr 3rd, 2025

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report report published on Monday morning. The firm issued a sell rating on the stock.

Navidea Biopharmaceuticals Price Performance

Shares of Navidea Biopharmaceuticals stock opened at $0.00 on Monday. Navidea Biopharmaceuticals has a one year low of $0.00 and a one year high of $0.13.

Navidea Biopharmaceuticals Company Profile

(Get Free Report)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

Read More

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.